title: An open-label comparison of the effects of simvastatin and niacin alone and combined on the lipid profile and lipoprotein (a) level in an Indian population with dyslipidemia.
abstract: Abstract.
  
  
  BACKGROUND
  Patients with dyslipidemia often require the use of >1 lipid-altering agent to achieve the target levels recommended by the National Cholesterol Education Program Adult Treatment Panel III.
  
  
  OBJECTIVE
  The aim of this study was to compare the effects of simvastatin and niacin alone and combined on the lipid profile and lipoprotein (a) (Lp[a]) level in an Indian population with dyslipidemia.
  
  
  METHODS
  This 12-week, open-label, nonrandomized study was conducted at the Departments of Pharmacology and Medicine, Government Medical College, Amritsar (Punjab), India. Patients aged 30 to 70 years with dyslipidemia were eligible. Patients were assigned to 1 of 3 treatment groups. Group 1 received simvastatin 20 mg/d for 12 weeks. Group 2 received niacin at doses of 375 mg/d for 1 week, 500 mg/d for 1 week, and 500 mg BID for 10 weeks. Group 3 received simvastatin 10 mg/d plus niacin (375 mg for 1 week and 500 mg for 11 weeks). The lipid profile (low-density lipoprotein cholesterol [LDL-C], high-density lipoprotein cholesterol [HDL-C], total cholesterol [TC], and triglycerides [TG]) and Lp(a) were measured before the start of therapy and at 6 and 12 weeks of treatment. Percentage changes from baseline were calculated. Adverse effects (AEs) were recorded at weeks 6 and 12 and through spontaneous reporting.
  
  
  RESULTS
  Ninety patients were enrolled (50 men, 40 women; 30 patients per treatment group). In group 1, the mean (SD) percentage decrease in LDL-C level at 12 weeks was 42.79% (16.29%) (P < 0.05), but no significant change was seen in group 2 or 3. The mean (SD) percentage increases in HDL-C level were 18.43% (13.28%) and 20.82% (17.57%) in groups 2 and 3, respectively (both, P < 0.05), but no significant change was seen in group 1. TC levels decreased by a mean (SD) of 32.97% (13.66%) in group 1 (P < 0.05), but no significant change was seen in group 2 or 3. TG and Lp(a) levels did not change significantly in any of the 3 treatment groups. Flushing, myalgia, and dyspepsia were the most common AEs in patients receiving niacin.
  
  
  CONCLUSIONS
  In this study in Indian patients with dyslipidemia, simvastatin-niacin combination therapy was associated with greater changes in lipid profile compared with either agent used alone. Niacin was also associated with greater changes in Lp(a) levels. AEs were less prevalent with combination therapy than with niacin alone.
authors.affiliation: Departments of Pharmacology and Medicine, Government Medical College, Amritsar (Punjab), India.
authors.forename: Kirandeep
authors.initials: K
authors.lastname: Kaur
authors.affiliation: Departments of Pharmacology and Medicine, Government Medical College, Amritsar (Punjab), India.
authors.forename: Jaswant
authors.initials: J
authors.lastname: Rai
authors.affiliation: Departments of Pharmacology and Medicine, Government Medical College, Amritsar (Punjab), India.
authors.forename: Geeta
authors.initials: G
authors.lastname: Sharma
authors.affiliation: Departments of Pharmacology and Medicine, Government Medical College, Amritsar (Punjab), India.
authors.forename: Baljinder Singh
authors.initials: BS
authors.lastname: Bal
keywords: combination therapy; dyslipidemia; niacin; simvastatin